IR-endocrinopathies are relatively frequent. Their management differs from other irAEs in three key ways: ICI therapy can be continued in most cases, high-dose CSs are rarely required and endocrine deficiency usually persists, necessitating lifelong replacement.
It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout